[go: up one dir, main page]

WO2021030153A3 - Engineered t cell receptors and uses thereof - Google Patents

Engineered t cell receptors and uses thereof Download PDF

Info

Publication number
WO2021030153A3
WO2021030153A3 PCT/US2020/045250 US2020045250W WO2021030153A3 WO 2021030153 A3 WO2021030153 A3 WO 2021030153A3 US 2020045250 W US2020045250 W US 2020045250W WO 2021030153 A3 WO2021030153 A3 WO 2021030153A3
Authority
WO
WIPO (PCT)
Prior art keywords
engineered
cell receptors
tcr
domain
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/045250
Other languages
French (fr)
Other versions
WO2021030153A2 (en
Inventor
Julyun OH
Chang Yi
Dora Toledo WARSHAVIAK
Jee Young MOCK
Mark DARIS
Agnes HAMBURGER
James Johnston
Carl Alexander Kamb
Aaron Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A2 Biotherapeutics Inc
Original Assignee
A2 Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A2 Biotherapeutics Inc filed Critical A2 Biotherapeutics Inc
Publication of WO2021030153A2 publication Critical patent/WO2021030153A2/en
Publication of WO2021030153A3 publication Critical patent/WO2021030153A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to fusion proteins comprising a transmembrane domain and an intracellular domain capable of providing a stimulatory signal, and engineered T cell receptors comprising same. The disclosure provides, in part, engineered T cell receptors (TCR) comprising one or more signaling domain(s) fused to the intracellular portion of at least one TCR subunit.
PCT/US2020/045250 2019-08-09 2020-08-06 Engineered t cell receptors and uses thereof Ceased WO2021030153A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885023P 2019-08-09 2019-08-09
US62/885,023 2019-08-09

Publications (2)

Publication Number Publication Date
WO2021030153A2 WO2021030153A2 (en) 2021-02-18
WO2021030153A3 true WO2021030153A3 (en) 2021-03-25

Family

ID=74571215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/045250 Ceased WO2021030153A2 (en) 2019-08-09 2020-08-06 Engineered t cell receptors and uses thereof

Country Status (1)

Country Link
WO (1) WO2021030153A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006962A (en) 2019-12-11 2022-09-12 A2 Biotherapeutics Inc CHIMERIC ANTIGEN RECEPTOR BASED ON MEMBER 1 OF THE LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR SUBFAMILY B (LILRB1).
EP4196493A1 (en) 2020-08-13 2023-06-21 A2 Biotherapeutics, Inc. Gene fusions for control of genetically modified cells
MX2023002041A (en) 2020-08-20 2023-04-27 A2 Biotherapeutics Inc COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS.
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
LT4058474T (en) 2020-08-20 2024-08-26 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCER
CA3207958A1 (en) 2021-02-16 2022-08-25 Julyun OH Compositions and methods for treating her2 positive cancers
CN117730091A (en) * 2021-04-13 2024-03-19 悟境股份有限公司 Improved chimeric antigen receptors and their uses
WO2024263818A2 (en) * 2023-06-20 2024-12-26 Immunova Therapeutics Llc Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039899A2 (en) * 2008-09-30 2010-04-08 University Of Southern California Method for monitoring intracellular tyrosine phosphatase activity
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20160311901A1 (en) * 2013-07-29 2016-10-27 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
WO2017096327A2 (en) * 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Compositions and methods for reducing immune responses against cell therapies
US20180010095A1 (en) * 2016-09-23 2018-01-11 Adaptimmune Limited T Cells with Increased Immunosuppression Resistance
WO2018067993A1 (en) * 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
WO2018193231A1 (en) * 2017-04-18 2018-10-25 Autolus Limited Cell
US20190022216A1 (en) * 2015-10-23 2019-01-24 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
WO2019067677A1 (en) * 2017-09-29 2019-04-04 Cell Design Labs, Inc. Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same
US20190240304A1 (en) * 2016-10-20 2019-08-08 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2010039899A2 (en) * 2008-09-30 2010-04-08 University Of Southern California Method for monitoring intracellular tyrosine phosphatase activity
US20160311901A1 (en) * 2013-07-29 2016-10-27 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
US20190022216A1 (en) * 2015-10-23 2019-01-24 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
WO2017096327A2 (en) * 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Compositions and methods for reducing immune responses against cell therapies
US20180010095A1 (en) * 2016-09-23 2018-01-11 Adaptimmune Limited T Cells with Increased Immunosuppression Resistance
WO2018067993A1 (en) * 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
US20190240304A1 (en) * 2016-10-20 2019-08-08 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
WO2018193231A1 (en) * 2017-04-18 2018-10-25 Autolus Limited Cell
WO2019067677A1 (en) * 2017-09-29 2019-04-04 Cell Design Labs, Inc. Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COURTNEY ADAM H., LO WAN-LIN, WEISS ARTHUR: "TCR SIGNALING: MECHANISMS OF INITIATION AND PROPAGATION", TRENDS IN BIOCHEMICAL SCIENCES, vol. 43, no. 2, February 2018 (2018-02-01), pages 108 - 123, XP055805438, DOI: 10.1016/j.tibs.2017.11.008 *

Also Published As

Publication number Publication date
WO2021030153A2 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
WO2021030153A3 (en) Engineered t cell receptors and uses thereof
MY202933A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
AU2018351050A8 (en) Compositions and methods for selective protein degradation
EP4438621A3 (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
HK1252163A1 (en) Receptor
EP3806889A4 (en) Cytokine fusion proteins and uses thereof
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
CY1120439T1 (en) BUSINESS INTERFACE polypeptides
HK1254820A1 (en) Immune checkpoint chimeric antigen receptors therapy
WO2009091826A3 (en) Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
NZ592420A (en) Cd86 antagonist multi-target binding proteins
MXPA06010500A (en) Anterior cervical plating system.
MX2018001497A (en) Factor ix fusion proteins and methods of making and using same.
EA201591731A1 (en) AGLCOOLED Fc-CONTAINING POLYPEPTIDES
MX2018015285A (en) Anti-b7-h3 antibodies and antibody drug conjugates.
EP3908664A4 (en) Multi-functional fusion proteins and uses thereof
MX2020007108A (en) Cell.
MX2020005170A (en) Vegfr-fc fusion protein formulations.
EP4368702A3 (en) Method of enhancing rna expression in a cell
WO2014055413A3 (en) A method of providing cellular therapy using modified natural killer cells or t lymphocytes
EP4431110A3 (en) Enhanced receptor for improving immune cell function
WO2020068196A3 (en) Proteins that inhibit cas12a (cpf1), a crispr-cas nuclease
SG11201900383RA (en) Pseudo-viral particles and uses of same
EP4512469A3 (en) Binding proteins to the human thrombin receptor, par4
MX2019009063A (en) Factor ix fusion proteins and methods of making and using same.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20853221

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20853221

Country of ref document: EP

Kind code of ref document: A2